Navigation Links
Sanofi Aventis: Study Shows Otamixaban Substantially Reduced Complications of Invasive Management of Acute Coronary Syndromes
Date:8/31/2009

II SEPIA-ACS1/ TIMI-42 study randomized 3241 patients from 36 countries in 6 treatment arms. The study assessed the efficacy and safety of five different doses of otamixaban versus the standard unfractionated heparin plus Glycoprotein IIb/IIIa inhibitor (eptifibatide), on background of standard dual antiplatelet therapy, in patients with high-risk non-ST-elevation acute coronary syndromes. SEPIA-ACS1 study showed that otamixaban displayed clinically meaningful activity on the primary endpoint from the threshold dose of 0.070 mg/kg/h, the second tested dose, with a consistent antithrombotic effect up to the 5th highest tested dosage. The lowest studied dosage was prematurely stopped due to insufficient activity, based on recommendation by an independent data monitoring board. Moreover a combined analysis of the intermediate doses (0.105 and 0.140 mg/kg/h) of otamixaban arms showed that otamixaban reduced by approximately 46 percent (p=0.0198) the risk of the composite of death or a second myocardial infarction, a predefined study secondary efficacy endpoint.

The potent antithrombotic effect of otamixaban was also accompanied with a dose-dependent bleeding profile. Combined intermediate otamixaban dosages showed a safety profile not statistically different with regard to TIMI major or minor bleeding through 7 days, in comparison to UFH and GPIIb/IIIa inhibitor comparator (RR 1.20, 95% CI 0.64-2.27, p=0.5634).

'The SEPIA-ACS1 trial is providing very encouraging results for a new and more effective treatment approach', said Marc Cluzel, MD Senior Vice President Research and Development sanofi-aventis. 'We aim, on the basis of these findings to address through our development program remaining patients', practionners' and payers' needs for management of ACS.'

Acute Coronary Syndromes is a general term used to regroup clinical symptoms related to acute myocardial ischemia. ACS represents an area of importa
'/>"/>

SOURCE Sanofi-aventis
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sanofi Pasteur Submits Supplemental Application for A(H1N1) Pandemic Vaccine to U.S. FDA
2. Sanofi-aventis Stands Behind the Safety of Lantus(R)
3. Sanofi Pasteur Dengue Vaccine Enters Pediatric Efficacy Clinical Study
4. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
5. Sanofi Aventis: People With Type 2 Diabetes Treated With LANTUS(R) and APIDRA(R) Achieved Greater Reductions in A1C Than Those Treated With Pre-mixed Insulin
6. Insulin Analogues From Novo Nordisk, Eli Lilly and Sanofi-Aventis Will Drive Growth in the Type 1 Diabetes Drug Market
7. Sanofi Pasteur Shipping First Doses of Influenza Vaccine for the 2008-2009 Season in the US
8. Sanofi Pasteur to Donate 60 Million Doses of H5N1 Vaccine to WHO Over 3 Years for its Influenza Vaccine Global Stockpile
9. Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
10. Sanofi Pasteur Receives FDA Approval of Meningococcal Vaccine for Children
11. Vical Licensee Sanofi-aventis Initiates Phase 3 Trial to Reduce Amputations
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Surgical Company (NASDAQ: STAA ) a leading ... systems for the eye today reported revenue for the ... a 10% increase over $18.2 million reported for the ... revenues grew 11% during the second quarter of 2014 ... of foreign currency exchange reduced sales by $0.1 million ...
(Date:7/31/2014)... 31, 2014 Xencor Inc. (NASDAQ: ... engineered monoclonal antibodies for the treatment of autoimmune ... reported financial results for the second quarter ended June ... business highlights. "In the second quarter, ... Society 2014 International Conference (ATS) demonstrating three novel ...
(Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
... NEW CENTERS AND TO ... INCREASE AWARENESS AMONG CARDIOLOGISTS, PLEASANTON, Calif., April 21 ... mechanical,circulatory support therapies to save, support and restore failing hearts,said ... (PreMarket,Approval) application, allowing the use of its HeartMate II LVAS ...
... April 21 A new study funded by,Health ... correlation,between dietary consumption of the omega-3 DHA* and ... Universite Laval,researchers and published in the Journal of ... pregnancy boosts an infant,s sensory,cognitive, and motor development., ...
Cached Medicine Technology:Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 2Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 3Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 4Thoratec Announces FDA Approval of HeartMate II(R) for Bridge-To-Transplantation 5Pregnant Women Need Omega-3 to Boost Infant Development 2
(Date:7/31/2014)... Implementation of an algorithm aimed to diagnose pediatric ... computed tomography (CT) scans, without affecting diagnostic accuracy, ... study was recently published in the journal ... common cause of acute abdominal pain in children. ... filled with pus. CT scans are often used ...
(Date:7/31/2014)... July 31, 2014 Setting goals for a ... blogs on successful tips to weight loss. Fitness on the ... over 8 years, and has worked with 6000 customers on ... have had the chance to monitor why customers start exercising ... how long they stick to their program, whether or not ...
(Date:7/31/2014)... Coral, FL (PRWEB) July 31, 2014 ... opportunity to take charge of their financial future. ... for women, has opened registration for 6 upcoming Los ... by women, for women, and with input from Kim ... Woman and It’s Rising Time) who is passionate about ...
(Date:7/31/2014)... 31, 2014 Today, Good Neighbor ... enhance patient care by kicking off another year ... The first of many education sessions and initiatives ... 2014, Good Neighbor Pharmacy and AmerisourceBergen’s annual conference. ... Services (CMS) Star Measures were a highlight and ...
(Date:7/31/2014)... Model moms are believers. PBS has a series dedicated ... field have grown exponentially in the last two decades. We’re ... are associated myths that need to be busted. , ... University . Celebrating 75 years in 2014, Frontier has the ... nation. “Frontier is changing the face of healthcare in the ...
Breaking Medicine News(10 mins):Health News:Fitness on the Go's Rewards Program Helps Clients Reach Their Goals 2Health News:The Independent Woman to Offer Financial Workshops in the Los Angeles Area - Developed by Women for Women 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 2Health News:Good Neighbor Pharmacy Reinforces Commitment to Helping Enhance Patient Care 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 2Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 3Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 4Health News:Frontier Nursing University Busts Midwifery Myths In Celebration of 75th Anniversary 5
... COVER: "Splitsville" (p. 46). Senior Editor David J. Jefferson ... classmates from Ulysses S.,Grant High School, class of ,82 ... interviews with former classmates, Jefferson tells the,stories of those ... the nuclear,family, the first for which divorce was just ...
... The Barbara Ann Karmanos,Cancer Institute researchers today presented, ... in San Diego, CA, the potential benefits,of Thymoquinone ... black seeds (Nigella,sativa), in treating pancreatic cancer., ... black seeds have been consumed in Asia, Africa ...
... April 12 Hundreds of,Service Employees International Union ... tonight, renouncing recent actions by the,California Nurses Association ... members made their voices heard during the Labor,Notes ... Rose,Ann DeMoro was scheduled to speak but cancelled ...
... condoms, vasectomy , , SATURDAY, April 12 (HealthDay News) -- For now, ... meager choices: A vasectomy -- meant to be permanent -- and ... is under development and that more choices will be here soon. ... off, but it,s getting closer. , "It has been ...
... with older, poorer, less educated populations likely due to ... , ANN ARBOR, Mich. More than a third of ... a huge increase from just a decade ago and a ... of Michigan study reveals major gaps in the availability of ...
... Home Operator Continuing to Jeopardize Residents, Care, ... Millbrae Convalescent Hospital will launch their second strike ... management,s unwillingness to,bargain fairly over the workers, proposals ... set to begin at 6 a.m. on Tuesday, ...
Cached Medicine News:Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 2Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 3Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 4Health News:NEWSWEEK: Media Lead Sheet/April 21, 2008 Issue (on newsstands Monday, April 14). 5Health News:Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component 2Health News:Karmanos Researchers Report Enhanced Chemosensitivity of Pancreatic Cancer Cells by Black Seed Component 3Health News:SEIU Members Stand Up for the Future of the Labor Movement and the Interests of All Workers 2Health News:Male Contraception: Progress Slow but Steady 2Health News:Male Contraception: Progress Slow but Steady 3Health News:National hospice study reveals gaps in service 2Health News:National hospice study reveals gaps in service 3Health News:National hospice study reveals gaps in service 4
Designed to provide comfortable support, protection and immobilization MCP joint along with immobilization of the wrist...
Design allows for easy-one hand application to provide support and immobilization of the wrist while preserving finger mobility...
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
Comfort Wrist Immobilizer with thumb abduction. 8"L, soft, padded comfort-type wrist immobilizer with dorsal metal stay. The thumb is held in abduction and splintered with a short metal stay....
Medicine Products: